STMN logo

Straumann Holding AG Stock Price

SWX:STMN Community·CHF 15.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 31 Fair Values set on narratives written by author

STMN Share Price Performance

CHF 0
-105.60 (-100.00%)
CHF 81.34
Fair Value
CHF 0
-105.60 (-100.00%)
Price CHF 0

STMN Community Narratives

·
Fair Value CHF 81.34 14.7% overvalued intrinsic discount

Rising Regulation And Cost Pressures Will Curb Premium Dental Demand

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value CHF 123 24.2% undervalued intrinsic discount

Emerging Markets And Aging Populations Will Redefine Dental Care

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value CHF 107.78 13.5% undervalued intrinsic discount

STMN: Future Performance Will Depend On U S Operational Recovery And Margin Stability

0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
CHF 81.34
14.7% overvalued intrinsic discount
Revenue
8.13% p.a.
Profit Margin
19.7%
Future PE
22.63x
Price in 2029
CHF 91.98
CHF 107.78
13.5% undervalued intrinsic discount
Revenue
8.26% p.a.
Profit Margin
20.13%
Future PE
29.51x
Price in 2029
CHF 123.03

Trending Discussion

Updated Narratives

STMN logo

STMN: Rich Multiples And Execution Risks Will Likely Cap Future Returns

Fair Value: CHF 81.34 14.7% overvalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
STMN logo

STMN: Higher Future P/E Assumptions Will Support Confidence In Execution Potential

Fair Value: CHF 123 24.2% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
STMN logo

STMN: Future Margin Delivery And Uplifted Growth Assumptions Support Renewed Optimism

Fair Value: CHF 107.78 13.5% undervalued intrinsic discount
15 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

1 Risk
2 Rewards

Straumann Holding AG Key Details

CHF 2.6b

Revenue

CHF 779.1m

Cost of Revenue

CHF 1.8b

Gross Profit

CHF 1.5b

Other Expenses

CHF 356.7m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 19, 2026
2.24
70.10%
13.69%
11.5%
View Full Analysis

About STMN

Founded
1954
Employees
11570
CEO
Guillaume Daniellot
WebsiteView website
www.straumann.com

Straumann Holding AG provides tooth replacement and orthodontic solutions in Switzerland, the United States, China, Germany, Brazil, Japan, France, and internationally. It operates through Sales Europe, Middle East and Africa; Sales North America; Sales Asia Pacific; Sales Latin America; and Operations segments. The company offers dental implants, instruments, CADCAM prosthetics, orthodontic and clear aligners, biomaterials, and digital equipment and solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. It also provides implant systems, components, and related instruments, as well as healing components, materials and surfaces, surgical sets and instruments, and guided surgery and navigation products; prosthetics, including angled solutions, connections, components, and molar solutions; intra-oral and lab scanners, milling machines, dynamic navigation systems, and 3D printers; consumables, such as blocks, discs, resins, titanium bases, and abutment blanks, as well as scan bodies, analogs, and sleeves; online education; and dentists and dental labs solutions. In addition, the company offers regenerative solutions for tooth preservation, implant-site management, and implant preservation; scanner hardware, software licenses, sterile-packaged products, customer training, and other products; and logistics and supply chain services. Further, it provides thermoplastics; implant treatment referral; high-tech materials; artificial intelligence solutions for dental applications; and 3D orthodontic treatment animations. The company sells its products under the Straumann, Neodent, Medentika, Anthogyr, ClearCorrect, NUVO, and other brands through a network of distribution subsidiaries and partners, and third-party distributors, as well as through its e-shop. It serves clinicals needs, patient segments, and healthcare systems. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

Recent STMN News & Updates

Narrative Update Jun 06

STMN: Rich Multiples And Execution Risks Will Likely Cap Future Returns

Straumann Holding's analyst price target has been nudged higher by CHF 1, as analysts highlight updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E, supported by recent incremental target increases from major banks. Analyst Commentary Recent research has focused on how fair value assumptions for Straumann Holding align with current market pricing, with some analysts trimming their estimates even as others make small upward adjustments to price targets.
Narrative Update May 22

STMN: Cautious CHF 81 Fair Value Will Likely Limit Near-Term Upside

The updated analyst price target for Straumann has been revised slightly higher to CHF 81.17 from CHF 80.00, as analysts factor in updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E following recent Street research updates. Analyst Commentary Recent Street research on Straumann Holding has included both higher and lower price targets, with some bearish analysts highlighting execution and valuation risks even as others adjust targets higher.
Narrative Update May 01

STMN: Higher Future P/E Assumptions Will Support Confidence In Execution Potential

Straumann's updated analyst price target holds around CHF 123, with recent small CHF 1 to CHF 3 adjustments from different banks reflecting analysts' mixed views on future growth, profit margins, and the appropriate P/E level for the shares. Analyst Commentary Recent Street research shows a mix of views on Straumann, with price targets clustering around CHF 79 to CHF 123 and opinions split on whether the current P/E is justified.

Recent updates

No updates